MR

Millie Ray

Life Sciences Company Creation

United States

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Genomics
Epigenetics
RNAseq
ChIP-seq
Stem Cells
Chromatin
Transcriptional Regulation
Transcriptomics
Cell
Biotechnology
Biochemistry
Protein Purification
CRISPR
Protein Chemistry
Laboratory
Microarray
Fluorescence Microscopy
Genetics
Statistics
Science

Education

Lists including Millie

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Casma Therapeutics

Series B

Total Funding: $160M

Hexagon Bio

Series A

Total Funding: $190M

Work Experience

TC
The Column Group

2017

  • Partner

    2022

  • Principal

    2019 - 2022

  • Associate

    2017 - 2018

Foghorn Therapeutics

2016 - 2017

  • Business Associate

    2016 - 2017

FV
Flagship Ventures - Venture Labs

2015 - 2016

  • Fellow and Associate

    2015 - 2016

MG
Massachusetts General Hospital

2008 - 2015

  • Graduate Student and Post- Doctoral Researcher- Kingston Lab

    2008 - 2015

BI
Broad Institute

2014 - 2015

  • Ebola Genomics team - Sabeti Lab

    2014 - 2015

    Implemented first Next Generation Sequencer to run in West Africa for high capacity Ebola surveillance and diagnostics tools.